| Cat. No. |
Product Name / Activity |
| 4274 |
AP 24534 |
| Identified as targeting human proteins in the SARS-CoV-2 interactome; potent multi-kinase and pan-Bcr-Abl inhibitor |
| 7283 |
Apilimod dimesylate |
| Inhibits cellular entry by SARS-CoV-2, MERS-CoV and MHV S pseudovirions; potent and selective PIKfyve inhibitor |
| 7235 |
Arbidol |
| Inhibits replication of SARS-CoV-2 in vitro; broad spectrum antiviral |
| 7755 |
Asunaprevir |
| Inhibits SARS-CoV-2 Mpro activity; also inhibits hepatitis C virus NS3 protease |
| 3771 |
Azithromycin |
| Predicted to disrupt binding of SARS-CoV-2 spike protein to ACE2 |
| 7222 |
Baricitinib |
| In silico modelling predicts inhibition of SARS-CoV-2 cell entry; highly potent JAK inhibitor |
| 3193 |
Camostat mesylate |
| Inhibits entry of SARS-Cov-2 into lung cells; TMPRSS2 inhibitor |
| 4109 |
Chloroquine diphosphate |
| Inhibits SARS-CoV-2 infection in vitro |
| 6357 |
Ciclesonide |
| Inhibits replication of SARS-CoV-2 in vitro; glucocorticoid |
| 0460 |
Cinanserin hydrochloride |
| Inhibits replication of SARS-CoV; Mpro inhibitor and 5-HT2 antagonist |
| 7485 |
Covidcil-19 |
| Inhibits viral propagation and viral infectivity of SARS-CoV-2 |
| 0970 |
Cycloheximide |
| Exhibits anti-MERS-CoV activity in vitro; protein synthesis inhibitor |
| 1101 |
Cyclosporin A |
| Inhibits coronavirus replication; cyclophilin inhibitor |
| 7223 |
Dabrafenib mesylate |
| Targets human proteins in the SARS-CoV-2 interactome; potent and selective B-Raf, CDK16 and NEK9 inhibitor |
| 6793 |
Dasatinib |
| Inhibits replication of SARS-CoV and MERS-CoV in vitro; potent pan-Src/Bcr-Abl inhibitor |
| 1467 |
Daunorubicin hydrochloride |
| Identified as targeting human proteins in the SARS-CoV-2 interactome; DNA topoisomerase II inhibitor |
| 4583 |
Digoxin |
| Exhibits anti-MERS-CoV activity in vitro; Na+/K+ ATPase inhibitor |
| 7336 |
Dinaciclib |
| Exhibits antiviral activity against SARS-CoV-2 in vitro; potent and selective inhibitor of CDK2, CDK5, CDK1 and CDK9 |
| 3807 |
Disulfiram |
| SARS-CoV-2 Mpro inhibitor; also reversibly stimulates SERCA Ca2+-ATPase |
| 4545 |
E 64d |
| Inhibts entry of SARS-CoV-2 into lung cells in combination with Camostat (Cat. No. 3193); cathepsin inhibitor |
| 5245 |
Ebselen |
| Inhibits SARS-CoV-2 Mpro in vitro; glutathione peroxidase mimic |
| 6986 |
EG 00229 trifluoroacetate |
| Inhibits binding of cleaved spike protein of SARS-CoV-2 to neuropilin 1 (NRP1); neuropilin 1 antagonist |
| 7231 |
EIDD 1931 |
| Inhibits MERS-CoV and SARS-CoV-2 replication in vitro; viral RNA-dependent RNA polymerase (RdRP) inhibitor |
| 7225 |
Favipiravir |
| Reduces infection rate of SARS-CoV-2 in vitro; viral RNA polymerase inhibitor |
| 3631 |
FK 506 |
| Identified as targeting human proteins in the SARS-CoV-2 interactome; potent calcineurin inhibitor |
| 7229 |
Galidesivir dihydrochloride |
| Broad spectrum antiviral nucleotide; inhibits coronavirus replication in vitro |
| 3259 |
Gemcitabine hydrochloride |
| Inhibits replication of coronaviruses; DNA synthesis inhibitor |
| 7280 |
GRL 0617 |
| Coronavirus PLpro inhibitor |
| 7227 |
GS 441524 |
| Displays antiviral activity against MERS-CoV, SARS-CoV and SARS-CoV-2; viral RNA-dependent RNA polymerase (RdRp) inhibitor; active metabolite of Remdesivir (Cat. No. 7226) |
| 5303 |
GSK 2194069 |
| Inhibits SARS-CoV-2 infection in vitro; human FASN inhibitor |
| 4618 |
GW 6471 |
| Blocks SARS-CoV-2 infection in vitro and reduces viral RNA; PPARα antagonist |
| 1416 |
Homoharringtonine |
| Inhibits SARS-CoV-2 infection in vitro; inhibits protein synthesis |
| 5648 |
Hydroxychloroquine sulfate |
| Inhibits SARS-CoV-2 viral infection in vitro |
| 5906 |
Imatinib mesylate |
| Inhibits replication of SARS-CoV and MERS-CoV in vitro; potent and selective v-Abl tyrosine kinase inhibitor |
| 1708 |
Indomethacin |
| Identified as targeting human proteins in the SARS-CoV-2 interactome |
| 1260 |
Ivermectin |
| Inhibits replication of SARS-Cov-2 in vitro; antiparasitic and antiviral |
| 4499 |
(+)-JQ1 |
| Inhibits ACE2 and TMPRSS2 transcription and blocks infection by SARS-CoV-2; potent and selective BET bromodomain inhibitor |
| 3765 |
Linezolid |
| Identified as targeting human proteins in the SARS-CoV-2 interactome; antibiotic |
| 5213 |
LL 37 |
| Inhibits interaction between SAR-CoV-2 S1 protein and ACE2; human cathelicidin peptide derivative |
| 0840 |
Loperamide hydrochloride |
| Inhibits replication of coronaviruses in vitro; peripherally acting μ opioid agonist and Ca2+ channel blocker |
| 7052 |
Lopinavir |
| Inhibits SARS-CoV-2 replication in vitro; highly potent and selective HIV-1 protease inhibitor |
| 7705 |
Masitinib |
| SARS-CoV-2 Mpro inhibitor |
| 6819 |
Mefloquine hydrochloride |
| Exhibits antiviral activities against SARS-CoV-2; also Cx36 and Cx50 gap channel blocker |
| 2864 |
Metformin hydrochloride |
| Identified as targeting human proteins in the SARS-CoV-2 interactome; antidiabetic |
| 7586 |
Molnupiravir |
| Prodrug of antiviral nucleoside analog; inhibits SARS-CoV, SARS-CoV-2 and MERS-CoV infection |
| 7853 |
Mpro 13b-H |
| Negative control for Mpro 13b-K (Cat. No. 7228) |
| 7228 |
Mpro 13b-K |
| Coronavirus Mpro inhibitor |
| 7695 |
Mpro 61 |
| Potent non-covalent inhibitor of SARS-CoV-2 main protease |
| 7230 |
MPro N3 |
| Coronavirus Mpro inhibitor |
| 3081 |
Nafamostat mesylate |
| Inhibits SARS-CoV-2 infection in vitro; serine protease inhibitor |
| 3766 |
Nelfinavir mesylate |
| Exhibits anti-MERS-CoV activity in vitro; potent HIV-1 protease inhibitor |
| 4079 |
Niclosamide |
| Inhibits SARS-CoV-2 spike protein induced syncytia formation and viral replication in vitro; also STAT3 inhibitor |
| 7234 |
Nitazoxanide |
| Inhibits SARS-CoV-2 infection in vitro; Pyruvate flavodoxin/ferredoxin oxidoreductase (PFOR) inhibitor |
| 1076 |
Ouabain |
| Exhibits anti-MERS-CoV activity in vitro; Na+/K+ ATPase inhibitor |
| 7505 |
PLpro inhibitor 19 |
| SARS-CoV-2 PLpro and viral replication inhibitor |
| 7357 |
PLpro inhibitor 6 |
| SARS-CoV and SARS-CoV-2 PLpro inhibitor |
| 4107 |
Probenecid |
| Inhibits SARS-CoV-2 replication and influenza A infection; MRP and OAT3 inhibitor |
| 1125 |
Quercetin |
| Inhibits SARS-CoV Mpro; also non-selective PI 3-kinase inhibitor |
| 1292 |
Rapamycin |
| Inhibits MERS-CoV infection; mTOR inhibitor and immunosuppressant |
| 7226 |
Remdesivir |
| Displays antiviral activity against MERS-CoV, SARS-CoV and SARS-CoV-2; viral RNA-dependent RNA polymerase (RdRp) inhibitor |
| 4501 |
Ribavirin |
| Inhibits cytopathic effect of SARS-CoV in vitro; guanosine analog and IMPDH inhibitor |
| 5856 |
Ritonavir |
| Improves outcome in an animal model of MERS-CoV infection; HIV protease inhibitor |
| 7064 |
Ruxolitinib |
| Targets human proteins in the SARS-CoV-2 interactome; potent and selective JAK1/JAK2 inhibitor |
| 7191 |
Santacruzamate A |
| Identified as targeting human host proteins that interact with SARS-CoV-2 |
| 7189 |
Saracatinib |
| Inhibits MERS-CoV, other coronaviruses and dengue virus |
| 7760 |
Selinexor |
| Potent inhibitor of SARS-CoV-2 replication in vitro |
| 7192 |
SMIP 004 |
| S-phase kinase-associated protein 2 (SKP2) inhibitor; inhibits MERS-CoV replication and induces autophagy in infected cells |
| 7554 |
SSYA10-001 |
| Potent coronavirus helicase inhibitor; also inhibits human papillomavirus E6 |
| 1138 |
Thapsigargin |
| Inhibits SARS-CoV-2 infection in vitro; SERCA inhibitor |
| 2815 |
Valproic acid, sodium salt |
| Identified as targeting human proteins in the SARS-CoV-2 interactome; HDAC inhibitor |
| 0654 |
Verapamil hydrochloride |
| Targets human proteins in the SARS-CoV-2 interactome; CaV1.x blocker |